| Autor: |
Fiorino, Gionata, Danese, Silvio, Peyrin‐Biroulet, Laurent, Sans, Miquel, Bonelli, Fabrizio, Calleri, Mariella, Zierold, Claudia, Pollastro, Roberta, Moretti, Fabio, Malesci, Alberto |
| Zdroj: |
United European Gastroenterology Journal; October 2022, Vol. 10 Issue: 8 p836-843, 8p |
| Abstrakt: |
Fecal calprotectin (FC) is established as a diagnostic marker to differentiate between inflammatory bowel diseases and non‐inflammatory conditions. Furthermore, it may be effective in monitoring response to treatment, and to predict relapse during maintenance therapy. This was a prospective longitudinal study carried out in Italy, France and Spain. The primary objective was to correlate the LIAISON®Calprotectin assay measurements to quiescent ulcerative colitis (UC) or relapse as assessed by clinical data. Patients were assessed every 3 months for 12 months, and at 18 months. The last FC measured prior to relapse was the variable that predicted relapse in a statistically significant manner. With a 62.3 μg/g cut‐off the area under the curve was 0.619, and the sensitivity was 62.9% (95% Confidence Interval [CI] 44.9%–78.5%) and specificity 63.0% (95% CI 53.1%–72.1%). Using machine learning methods, the last FC measurement was shown to have the largest impact in predicting relapse. An algorithm was developed that included other variables available following a clinician's visit, which resulted in an area under the curve of 0.754 for predicting relapse. In the present study FC measured by the LIAISON®Calprotectin assay on the visit before relapse is predictive of relapse in patients with quiescent UC. In a proof of concept, the accuracy of prediction can further be improved including other variables in an algorithm developed by machine learning. The trial is registered at clinicaltrials.govwith reference number NCT05168917. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Plný text